Abstract
Objective: To evaluate the clinical and paraclinical characteristics, disease control outcomes, and safety profile of maintenance olaparib therapy in real-world clinical practice at K Hospital. Methods: A retrospective–prospective descriptive cohort study with longitudinal follow-up was conducted in 69 patients with stage III–IV epithelial ovarian cancer who received maintenance therapy with olaparib (with or without bevacizumab) between January 2021 and December 2025. Results: The median age was 59 years. High-grade serous carcinoma was the predominant histological subtype (97.1%). BRCA1/2 mutations were detected in 65.3% of patients (BRCA1: 52.2%; BRCA2: 13.1%). The median progression-free survival (PFS) was 41.1 months (95% CI: 35.5–NA). Multivariable Cox regression analysis identified ECOG performance status 1 as an independent predictor of disease progression (HR = 11.46; p < 0.001), whereas the presence of a BRCA mutation was a strong independent protective factor (HR = 0.11; p = 0.003). Anemia was the most common adverse event (59.4%), with grade ≥3 anemia occurring in 5.8% of patients. Dose interruption and dose reduction rates were low, at 7.2% and 5.8%, respectively. Conclusions: Maintenance therapy with olaparib following cytoreductive surgery and platinum-based chemotherapy provided durable disease control, demonstrated a favorable safety profile, and was feasible in routine clinical practice for patients with advanced epithelial ovarian cancer.
References
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clinicians. 2021;71(3):209-249. doi:10.3322/caac.21660
National Comprehensive Cancer Network. Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer (Version 4.2026). Published online 2026. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453
Perren TJ, Swart AM, Pfisterer J, et al. A Phase 3 Trial of Bevacizumab in Ovarian Cancer. N Engl J Med. 2011;365(26):2484-2496. doi:10.1056/NEJMoa1103799
Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017;355(6330):1152-1158. doi:10.1126/science.aam7344
Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495-2505. doi:10.1056/NEJMoa1810858
Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Annals of Oncology. 2023;34(8):681-692. doi:10.1016/j.annonc.2023.05.005
Chase D, Perhanidis J, Gupta D, Kalilani L, Golembesky A, González-Martín A. Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance. Oncol Ther. 2023;11(2):245-261. doi:10.1007/s40487-023-00227-6
| Published | 18-08-2026 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 18 No. 5 (2026) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.18.5.10 | |
| Keywords | ung thư biểu mô buồng trứng, olaparib, bevacizumab, BRCA1/2 |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Journal of Clinical Medicine Hue Central Hospital